Zhengye Biotechnology (ZYBT) Competitors $6.98 +0.28 (+4.18%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock ZYBT vs. SDGR, EWTX, HROW, ARDX, ETNB, ABCL, VERA, SPRY, AMPH, and COGTShould you be buying Zhengye Biotechnology stock or one of its competitors? The main competitors of Zhengye Biotechnology include Schrodinger (SDGR), Edgewise Therapeutics (EWTX), Harrow (HROW), Ardelyx (ARDX), 89BIO (ETNB), AbCellera Biologics (ABCL), Vera Therapeutics (VERA), ARS Pharmaceuticals (SPRY), Amphastar Pharmaceuticals (AMPH), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry. Zhengye Biotechnology vs. Its Competitors Schrodinger Edgewise Therapeutics Harrow Ardelyx 89BIO AbCellera Biologics Vera Therapeutics ARS Pharmaceuticals Amphastar Pharmaceuticals Cogent Biosciences Schrodinger (NASDAQ:SDGR) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment. Does the media favor SDGR or ZYBT? In the previous week, Schrodinger had 11 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 17 mentions for Schrodinger and 6 mentions for Zhengye Biotechnology. Schrodinger's average media sentiment score of 0.34 beat Zhengye Biotechnology's score of 0.00 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer SDGR or ZYBT? Schrodinger currently has a consensus price target of $27.83, suggesting a potential upside of 36.98%. Given Schrodinger's stronger consensus rating and higher possible upside, equities analysts plainly believe Schrodinger is more favorable than Zhengye Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Schrodinger 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Zhengye Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings and valuation, SDGR or ZYBT? Zhengye Biotechnology has lower revenue, but higher earnings than Schrodinger. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSchrodinger$207.54M7.21-$187.12M-$2.48-8.19Zhengye Biotechnology$25.53M12.90$1.55MN/AN/A Is SDGR or ZYBT more profitable? Zhengye Biotechnology has a net margin of 0.00% compared to Schrodinger's net margin of -76.22%. Zhengye Biotechnology's return on equity of 0.00% beat Schrodinger's return on equity.Company Net Margins Return on Equity Return on Assets Schrodinger-76.22% -45.70% -24.81% Zhengye Biotechnology N/A N/A N/A Do insiders and institutionals have more ownership in SDGR or ZYBT? 79.1% of Schrodinger shares are owned by institutional investors. 21.0% of Schrodinger shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummarySchrodinger beats Zhengye Biotechnology on 8 of the 13 factors compared between the two stocks. Get Zhengye Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYBT vs. The Competition Export to ExcelMetricZhengye BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$316.02M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E RatioN/A20.8831.1026.04Price / Sales12.90343.33433.45102.77Price / Cash65.0243.1937.7358.48Price / Book6.848.129.536.61Net Income$1.55M-$54.72M$3.26B$265.56M7 Day Performance-7.06%2.63%2.10%1.97%1 Month Performance20.76%2.78%2.81%-0.36%1 Year PerformanceN/A11.01%30.56%19.03% Zhengye Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYBTZhengye BiotechnologyN/A$6.98+4.2%N/AN/A$316.02M$25.53M0.00278News CoverageGap DownSDGRSchrodinger3.1095 of 5 stars$19.40-3.2%$27.83+43.5%+4.3%$1.48B$207.54M-7.82790EWTXEdgewise Therapeutics2.5965 of 5 stars$13.80-1.4%$40.55+193.8%-24.2%$1.47BN/A-8.9060Analyst ForecastHROWHarrow3.6473 of 5 stars$38.23-0.2%$64.67+69.2%-5.3%$1.42B$227.66M-152.92180Analyst RevisionARDXArdelyx4.3303 of 5 stars$5.86+0.9%$11.50+96.2%+1.0%$1.40B$333.61M-25.4890Positive NewsETNB89BIO2.0198 of 5 stars$9.00-4.7%$26.29+192.1%+11.3%$1.40BN/A-2.4940ABCLAbCellera Biologics2.2936 of 5 stars$4.29-8.1%$8.00+86.5%+74.9%$1.40B$32.88M-7.80500Gap UpVERAVera Therapeutics3.7509 of 5 stars$22.07+1.2%$63.00+185.5%-42.3%$1.39BN/A-6.1640Positive NewsSPRYARS Pharmaceuticals2.455 of 5 stars$13.79-1.7%$31.00+124.8%+5.4%$1.39B$89.15M-28.1490Insider TradeAMPHAmphastar Pharmaceuticals3.4489 of 5 stars$30.33+1.9%$31.50+3.9%-35.4%$1.38B$731.97M11.362,028Positive NewsCOGTCogent Biosciences3.6326 of 5 stars$11.76-2.9%$18.70+59.0%+24.7%$1.38BN/A-6.6180Positive News Related Companies and Tools Related Companies SDGR Alternatives EWTX Alternatives HROW Alternatives ARDX Alternatives ETNB Alternatives ABCL Alternatives VERA Alternatives SPRY Alternatives AMPH Alternatives COGT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZYBT) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zhengye Biotechnology Holding Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zhengye Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access